Start · Catalogue · Profile · Table
Breathing BODY HANDBOOK
Breathing · §26
Vaping (E-Cigarettes)
Vaping is two products dressed as one. For a current smoker, it's one of the most effective quit aids that exists — switching fully captures most of the years cigarettes were going to take. For someone who has never smoked, it's a new nicotine addiction with nothing on the other side of the ledger, and a long-term safety profile no one has lived long enough to measure. The middle case — off cigarettes, on the vape, can't come off the vape — is what most vapers actually live.
Decide · Course Evidence Moderate Chapter Breathing

The cessation question has a clean answer: in head-to-head trials a refillable vape beats every nicotine product your pharmacy sells, by a wide margin. The body-harm question doesn't: short-term heart-rate and airway-irritation signals are real but smaller than smoking, and nobody has been on a vape for thirty years yet — the long-term math is genuinely unwritten. Read this if you smoke, want out, and are deciding whether the vape is your tool. Or if you've never smoked and someone has told you vaping is harmless.

The simplest framing: a cigarette burns tobacco at roughly 900 °C and produces more than seven thousand chemicals, including dozens of known carcinogens, tar, and carbon monoxide. A vape heats a liquid — nicotine plus propylene glycol, vegetable glycerin, and flavours — at about a fifth of that temperature, makes a fog of it, and you breathe it in. No combustion. The nicotine still reaches your blood within a few minutes; almost everything else in cigarette smoke doesn't (Goniewicz 2014).

What's still in the aerosol matters. Trace metals from the heating coil. Aldehydes that propylene glycol produces when it overheats. Flavour molecules — diacetyl, cinnamaldehyde, vanillin — that nobody studied as something to inhale for years before they were sold as something to inhale. And the nicotine itself, which constricts blood vessels, raises heart rate, and is genuinely addictive whether it arrives by combustion or aerosol. The honest framing isn't safe — it's far less of the worst stuff, plus some new stuff we don't fully understand.

What a puff actually does, on the felt-experience side: a small alertness lift in the minute or two after — sharper edges on the next email, slightly faster reaction times — paired with a quick calming hit and a small mood smoothing. That's nicotine working on the same receptors a cigarette would have, just delivered without the smoke. None of this is a baseline shift; it's the dose tugging you above your starting line for fifteen or twenty minutes, then leaving you slightly below it as it wears off. In a regular user, the felt benefit of any single puff is mostly your dependence going back to quiet — what looks like focus or calm from the inside is largely the withdrawal you didn't notice was starting.

Does it actually help you quit?

This is the part that's surprisingly settled. The Cochrane Collaboration — the gold standard for medical evidence reviews — looked at eighty-eight trials covering roughly twenty-seven thousand smokers and concluded, with high certainty, that nicotine-containing vapes help people quit cigarettes better than the patches, gum, and lozenges your pharmacy sells (Hartmann-Boyce et al. 2024). The effect size is large enough to put vaping in the same bracket as prescription cessation drugs.

The shorter-term picture on what vaping does to your body, separately from whether it helps you quit, is messier. Heart rate goes up a few beats after a session. Blood pressure ticks up a few millimetres of mercury. Long-term-user studies find lower respiratory symptoms than smokers and higher than never-users — the direction-of-effect is real, the magnitude is small compared with cigarettes (Banks et al. 2023) (Mohammadi et al. 2022). What no one has is a thirty-year cohort. The modern vape is from 2007. The cancer-and-COPD answer for someone who starts vaping at twenty-five and stops at fifty-five is a question the data can't yet answer.

Who this is actually for

Two readers have opposite expected-value calculations on the same product.

If you currently smoke cigarettes. The math is uncomplicated. Switching fully — no cigarettes, just vapes — drops the part of smoking that kills you (the smoke, the tar, the carbon monoxide) and keeps the part you got hooked on (the nicotine). On the most generous reading, you get most of the way to I quit smoking. On the harshest reading, you've traded a heart attack at sixty-five for something we don't yet know enough about. Either reading puts the trade firmly in your favour, and the U.K.'s Royal College of Physicians said exactly that (RCP 2016). And if early lung disease is already on the table — a smoker's cough that won't quit, the first signs of COPD — getting off the smoke is the highest-value move you can make, and the vape can be the bridge that gets you there.

If you've never smoked. None of that benefit is on the table. Whatever the long-term cost of vaping turns out to be — modest, large, somewhere between — you're buying it against nothing. The less harmful than cigarettes framing doesn't apply, because it's a comparison to a baseline you don't have. The honest answer is the boring one: don't start. This is also the U.S. Surgeon General's position for adolescents, and it generalises to anyone whose alternative is no tobacco product at all (U.S. Surgeon General 2016).

What people get wrong

"It's just as harmful as cigarettes." Roughly six in ten U.S. adults now believe this; it was about one in eight a decade ago. The biomarker work is unambiguous in the other direction — full switchers excrete a small fraction of the lung-cancer-relevant chemicals smokers do, often approaching never-smoker levels within weeks (Goniewicz et al. 2018). The misconception is downstream of two things: youth-uptake coverage and the EVALI panic. Both real concerns, neither evidence that a single puff of nicotine vapour is biologically equivalent to a single puff of cigarette smoke.

"Popcorn lung." The disease is real — bronchiolitis obliterans — and it was first documented in microwave-popcorn factory workers exposed to diacetyl at airborne concentrations thousands of times anything you'd get from a vape. It has never been documented from vaping. The phrase persists because it's vivid and easy to remember.

"EVALI — vaping put teenagers in the ICU." EVALI was an acute lung-injury outbreak in late 2019 that did exactly that — 2,807 hospitalisations, 68 deaths in the U.S. — and the cause was traced to vitamin E acetate, a thickener used in illicit THC cartridges. The CDC found it in the lung-fluid samples of 48 of 51 patients and zero of 99 controls (Blount et al. 2020). Not nicotine vapes. The misattribution stuck because the news cycle stuck.

If you're using it to quit cigarettes

This is the protocol that did the work in the NHS trial that put vaping in U.K. guidelines.

Heavy disposable use runs $30–80 a month — cheaper than cigarettes in places with high tobacco tax (the U.K., Australia, France), roughly on par in most of the U.S., more expensive than cigarettes in low-tax countries. A refillable system pays for itself fast: a $20–40 mod plus bulk liquid amortises to under $20 a month for an established user. The active effort is the cessation course itself — a few weeks of choosing the device over the cigarette pack — plus the small daily friction of keeping the thing charged and topped up. Availability is the messy bit: in the U.S. most vapes for sale are technically pending or denied FDA authorisation but stay on convenience-store shelves; in Australia, nicotine vapes are prescription-only; the EU caps tank size and nicotine strength; the U.K. is the relatively liberal market that built the cessation infrastructure to match.

Where this goes wrong

Two failure modes swallow most attempts.

Dual use. You buy a vape. You keep smoking, you smoke less. This is the version of vaping that doesn't work — the biomarker data on dual users looks closer to smokers than to switchers, and the respiratory-symptom data tracks the same way. The decision is binary: cigarettes go, or the switch isn't doing the thing it could do.

Never coming off the vape. Four out of five successful quitters in the trials were still vaping a year later (Hajek et al. 2019). Pod and disposable systems are designed to be more rewarding than cigarettes, not less: you can use them indoors, anywhere, in shorter increments, with sweeter taste — and nicotine-salt liquids deliver the hit without the throat irritation that originally limited cigarette puff size. Coming off the vape is a separate project from coming off cigarettes, and the cessation literature is much thinner on it. Worth knowing going in: the vape may be a stop you're on for years.

What changes if you switch

The first week, your taste and smell come back. People who haven't smelled coffee properly in a decade often describe this as the surprise — food gets stronger, the morning routine starts smelling like a morning routine. Your partner stops mentioning the smell on your clothes.

By a month or two, the morning cough fades. The chronic throat-clearing goes. Walking up the stairs to your flat stops being the workout it had quietly become. Urine tests for the lung-cancer-relevant tobacco chemicals show them falling to roughly never-smoker levels within four weeks of fully switching (Goniewicz et al. 2018).

By a year, exercise tolerance has rebuilt. The friends and family who didn't say anything for years comment now — you look healthier, you don't smell, you're not the person standing outside restaurants in the rain anymore. Cardiovascular risk has started the slow bend back toward baseline, the same bend that follows cigarette quitting more broadly: partial in the first year, mostly complete over a decade.

By a decade — the part the trials can't yet see directly — most of the life expectancy cigarettes were going to take is back on the table, provided you stay switched. The asterisk that doesn't disappear: you're still using nicotine. Most people who switch end up using it for years.

Adjacent territory this entry doesn't cover. Nicotine-replacement therapy — patches, gum, lozenges — as the standalone path for smokers who want no nicotine vehicle at all. Varenicline and bupropion as prescription cessation drugs, both with stronger one-year outcomes than NRT alone. Cannabis vaping, which is a genuinely different product with a different chemistry and a different risk profile. Heated-tobacco products (IQOS, glo), which sit between cigarettes and vapes — partial combustion of real tobacco rather than aerosolised liquid. And the regulatory patchwork — the U.S. PMTA process, the EU's nicotine and tank-size caps, Australia's prescription-only model — which is the under-discussed reason your local vape shop looks the way it does.

Related in the handbook
Worsens / aggravates
  • — The aerosol dries the mouth and irritates the gums. It's gentler than smoke, but it isn't nothing for your gum line.
Helps
  • — If lung disease is already on the table, getting off cigarettes is the move; a vape can be the bridge.
Alternatives
  • — If you smoke, a full switch to vaping is one of the most effective quit aids there is; if you don't, there's no upside.
Related
  • — The thing keeping you on the vape is nicotine on your reward circuit; the hardest part is coming off it.
·
26